LIGAND PHARMACEUTICALS INC files DEF 14A

Ligand Pharmaceuticals Incorporated is holding its annual meeting on June 5, 2026, to elect eight directors, ratify Ernst & Young LLP as its independent auditor, approve named executive officer compensation on an advisory basis, and approve an amendment and restatement of the Company’s 2002 Stock Incentive Plan. The company delivered exceptional financial performance in 2025, with full-year adjusted EPS exceeding original guidance by more than 30% and royalty revenue growing 48% over the prior year.